Revelation Biosciences Inc

Revelation Biosciences, Inc. is a clinical-stage life science company focused on rebalancing inflammation to optimize health. Its lead product candidate is Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. The company develops and commercializes therapeutics that modulate the innate immune system, including GEM-AKI for the prevention and treatment of acute kidney injury and GEM-CKD for the prevention and treatment of chronic kidney disease. Formerly known as Petra Acquisition, Inc., it changed its name to Revelation Biosciences, Inc. in January 2022, was incorporated in 2019, and is based in San Diego, California.